Stock Split History
How to Retire on Monthly Dividends »    KZIA Historical Stock Prices »



Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Kazia Therapeutics is an oncology-focused biotechnology company that has a portfolio of development candidates in a range of oncology indications. Co.'s primary development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase/Akt/mTor pathway, that is being developed as a potential therapy for glioblastoma as well as other forms of brain cancer. Paxalisib is orally administered and is presented in a 15mg capsule formulation. Co.'s second development candidate is EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. EVT801 selectively targets lymphangiogenesis, the formation of new lymphatic vessels. According to our Kazia Therapeutics stock split history records, Kazia Therapeutics has had 1 split.
Kazia Therapeutics stock split history picture
Kazia Therapeutics (KZIA) has 1 split in our Kazia Therapeutics stock split history database. The split for KZIA took place on July 14, 2017. This was a 1 for 4 reverse split, meaning for each 4 shares of KZIA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.

When a company such as Kazia Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the Kazia Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kazia Therapeutics shares, starting with a $10,000 purchase of KZIA, presented on a split-history-adjusted basis factoring in the complete Kazia Therapeutics stock split history. Kazia Therapeutics split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/28/2014
End date: 04/24/2024
Start price/share: $15.96
End price/share: $0.39
Dividends collected/share: $0.00
Total return: -97.56%
Average Annual Total Return: -31.01%
Starting investment: $10,000.00
Ending investment: $244.51
Years: 10.00
Date Ratio
07/14/20171 for 4
iSun, Inc. (ISUN)
Avenue Therapeutics, Inc. (ATXI)
Bakkt Holdings, Inc. (BKKT)
Applied DNA Sciences, Inc. (APDN)
Cidara Therapeutics, Inc. (CDTX)
Smart for Life, Inc. (SMFL)
Windtree Therapeutics, Inc. (WINT)
Golden Sun Health Technology Group Limited (GSUN)
Zapp Electric Vehicles Group Limited (ZAPP)
Beneficient (BENF)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »
Funds Holding Kazia Therapeutics

Kazia Therapeutics Stock Split History | www.StockSplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.StockSplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.